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What are the novel findings of this work? 
Arterial stiffness is a prognostic marker for cardiovascular disease. Women who 
develop HDP have higher AIx compared to normotensive controls and AIx is highest 
in those with an associated SGA neonate.  
 
What are the clinical implications of this work? 
Measuring AIx could help identify those most at risk of SGA and later life 
cardiovascular disease. 
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ABSTRACT 
Objective:  Pregnancies complicated by preeclampsia with a small for gestational 
age (SGA) neonate have poorer hemodynamic function compared to women with 
hypertensive disorders of pregnancy (HDP) and an appropriately grown neonate. 
Arterial stiffness is a recognised prognostic marker of cardiovascular disease in the 
general population. The aim of this study was to compare arterial stiffness in 
hypertensive pregnancies with and without SGA fetuses. 
Methods: This was a prospective case control study of hypertensive and healthy 
normotensive pregnancies. Arterial stiffness, as assessed by pulse wave velocity 
(PWV) and aortic augmentation index (AIx), was recorded using a non-invasive 
device (Arteriograph®). Maternal and hemodynamic factors were adjusted for using 
linear regression analysis. Comparisons between groups were carried out using 
Mann-Whitney or Chi-Square (or Fisher’s exact) test for categorical variables. 
Results: Sixty-nine patients with HDP with SGA, 129 patients with HDP with a 
normally grown fetus and 220 healthy controls were included in the analysis. 
Maternal age, weight, height and heart rate were significantly associated with 
brachial and aortic AIx, whilst maternal weight, height, mean arterial pressure, heart 
rate and gestational age were significant predictors of aortic PWV.  Both the HDP 
with SGA and HDP-only groups had significantly higher adjusted aortic AIx 
compared to controls (12.5% and 10.0% vs. 7.6%; both p<0.05) and were 
significantly different to each other (P=0.002).  
Adjusted PWV was significantly higher in the HDP-only group compared to the 
control group and the HDP with SGA group (7.7m/s vs. 7.1m/s and 7.1m/s, both 
p<0.001). Conversely, the unadjusted value was not significantly different between 
the two hypertensive groups (p=0.414).  
Conclusions: Pregnancies complicated by HDP with SGA or HDP-only have 
significantly higher aortic AIx compared to uncomplicated normotensive pregnancies. 
Aortic AIx was highest in those pregnancies complicated by preeclampsia with SGA, 
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reflecting a progression in severity of arterial stiffness abnormality with a worsening 
clinical picture. These findings most likely reflect systemic reduced vascular 
compliance and increased systemic vascular resistance in HDP pregnancies. 
 
Introduction 
Women who have pregnancies complicated by preeclampsia and gestational 
hypertension are at an increased risk of both hypertension and cardiovascular 
disease in later life.1–4 Furthermore, the subsequent risk of developing hypertension 
or cardiovascular disease correlates with the severity of the preeclampsia that these 
women sustain. A large systematic review and meta-analysis found that the relative 
risk of developing ischaemic heart disease following preeclampsia is 2.17 (1.92-2.45) 
compared to women with normotensive pregnancies. However, for women who 
develop preterm preeclampsia (<37 weeks), this is increased to 7.71 (4.40-13.52).2 
Women who develop preterm preeclampsia also have more modifiable 
cardiovascular risk factors than women with term preeclampsia.5 In addition to the 
gestational onset of preeclampsia, the co-existence of fetal growth restriction is also 
a marker of disease severity.6,7 We have recently demonstrated that pregnancies 
complicated by preeclampsia with a small for gestational age (SGA) neonate have 
worse hemodynamic function than pregnancies with preeclampsia or gestational 
hypertension alone (under review).  
 
Arterial stiffness is a marker of vascular health and is a prognostic marker for 
cardiovascular disease in the general population.8,9 Both pulse wave velocity (PWV), 
which is a direct measure of arterial stiffness, and augmentation index (AIx), which is 
a surrogate measure of arterial stiffness, can be measured non-invasively in 
pregnancy. We, and others, have demonstrated increased arterial stiffness before 
and during the clinical stage of preeclampsia.10–16 However, it is less clear if arterial 
stiffness differs with the varying severity of the clinical picture. If this were the case it 
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would add to our understanding of the role of cardiovascular health in the 
development of preeclampsia. The aim of this study was therefore to investigate 
PWV and AIx in pregnancies complicated by hypertensive disorders of pregnancy 
(HDP) with and without a SGA neonate and in normotensive control pregnancies. 
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Methods 
Study population and recruitment 
This was a prospective case control study of pregnancies complicated by 
preeclampsia or gestational hypertension and normotensive control pregnancies 
presenting to a tertiary referral hospital between January 2012 and May 2018. The 
inclusion criteria were singleton pregnancies with a viable fetus at 20 weeks’ 
gestation or greater with gestational hypertension or preeclampsia, defined 
according to the ISSHP 2014 revised criteria:17 
• Gestational Hypertension: ‘de novo hypertension (≥140/90 mmHg) after 20 
weeks gestation.’ 
• Preeclampsia: ‘‘de novo hypertension (≥140/90 mmHg) after 20 weeks 
gestation with the coexistence of proteinuria, other maternal organ 
dysfunction or fetal growth restriction.’ 
The exclusion criteria were women with multiple pregnancies, a history of chronic 
hypertension or cardiac disease and pregnancies complicated by aneuploidy, 
genetic syndromes or major structural fetal abnormalities. A small for gestational age 
neonate was defined as having a birthweight below the 10th centile. All Pregnancies 
were dated according to crown–rump length measurement in the first trimester in 
accordance with national guidelines.18 When the first ultrasound examination was 
performed after 14 weeks' gestation, pregnancies were dated according to head 
circumference measurement.19 
Patients were recruited at or shortly after they were first diagnosed with hypertension 
in pregnancy. The majority of patients were recruited from the obstetric assessment 
unit, with some recruited from antenatal clinic or as inpatients. They were assigned a 
diagnosis as per the above criteria. Birthweight was obtained from hospital records 
and women with preeclampsia or gestational hypertension were divided into two 
groups: those who had a small for gestational age neonate (HDP with SGA) and 
those with an appropriately grown neonate (HDP-only). According to the modified 
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ISSHP criteria, those in the SGA group had preeclampsia whilst those in the 
hypertension-only group had either gestational hypertension or preeclampsia. 
Therefore, the final diagnosis for the study was confirmed after delivery. The control 
group had no pre-existing cardiac or metabolic disease. Those control pregnancies 
that subsequently developed hypertension or resulted in the birth of a small for 
gestational age neonate were excluded from the analysis. Patients in the control 
group were recruited whilst attending a routine antenatal visit or a third trimester 
ultrasound assessment (placental localisation, presentation, measuring small or 
large for dates on fundal height measurement). Those that had an ultrasound were 
only included if the ultrasound demonstrated a normally grown fetus with normal 
liquor volume and Doppler measurements. Written consent was obtained from all 
study participants and research ethics committee approval (12/LO/0810) was 
obtained prior to performing the study investigations. 
 
Research Investigations 
All arterial stiffness measurements for this project were obtained using the 
Arteriograph® device (TensioMed, Budapest, Hungary). This is a non-invasive, 
oscillometric arterial stiffness device that uses a brachial arm cuff to detect pressure 
changes in the brachial artery. The device works by first inflating the cuff to measure 
brachial blood pressure. It then continues to inflate to 35mmHg above the systolic 
blood pressure. By inflating to suprasystolic pressure, the cuff completely occludes 
the brachial artery. The energy of the arterial waveform that was travelling towards 
the point of occlusion is instead transmitted to the surrounding upper arm soft tissue. 
As this is largely composed of fluid, making it incompressible, the energy is 
transmitted to the skin surface. As the skin under the cuff expands with the increased 
pressure, the cuff is compressed. This reduction in cuff volume is converted to an 
increase in pressure which is detected by the sensors of the device and transmitted 
via a Bluetooth connector to a computer where it is displayed on the software 
programme as a pressure waveform. By completely occluding the brachial artery, 
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any local arterial wall changes which may influence the pressure changes are 
omitted. From the pressure waveform, both PWV and AIx can be calculated. Aortic 
PWV was calculated as: the aortic length/time delay between two waveforms. The 
aortic length was calculated from the jugular-symphysis distance using a formula 
based on patient height provided by the device manufacturer. AIx was calculated as: 
pulse pressure/(pulse pressure-augmentation pressure) x 100. Brachial AIx was a 
direct calculation from the waveform and aortic AIx was obtained by the 
Arteriograph® software’s inbuilt generalised transfer function. 
Maternal height (m), weight (kg) and brachial blood pressure (mmHg) were obtained 
prior to the arterial stiffness assessment. Blood pressure (BP) was recorded based 
on guidance from the British and Irish Hypertension Society.20 Patients were seated 
quietly for 5 minutes prior to measurements being performed. A validated  upper arm 
automatic blood pressure monitor (Microlife®, Microlife AG Swiss Corporation, 
Switzerland) was used with an appropriately sized cuff. The patient’s arm was 
supported at the level of the heart. Mean arterial pressure (MAP) was calculated as 
2x diastolic BP + systolic BP /3. Arterial stiffness measurements were recorded from 
the patient’s right arm whilst lying still on a couch in a semi-recumbent position. 
Participants were asked to refrain from moving or talking during the measurement to 
allow for a good quality reading. The patient’s arm circumference was measured with 
a tape measure to ensure the correct size cuff was used. Readings with PWV 
standard deviation less than 0m/s or greater than 1m/s were excluded as these are 
deemed to represent poor quality readings, as per the manufacturer’s advice. A 
repeat measurement was taken and if the reading was insufficient on three 
occasions, the procedure was abandoned. Each reading was critically reviewed for 
quality prior to being included in the study. This included an assessment of the PWV 
standard deviation, as described above, and of the waveform pattern to ensure there 
was no artefact. All measurements were performed by trained operators. 
The Arteriograph® device was launched in 2005 and has been compared to both 
invasive techniques and alternative non-invasive techniques. Horvarth et al. 
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compared the Arteriograph® measurements of AIx, PWV and central systolic blood 
pressure (sBPAo) to invasively-recorded measurements obtained via intra-aortic 
catheterisation in 16, 55 and 22 patients undergoing routine coronary angiography, 
respectively.21 They reported strong correlation between the measurements (r=0.94, 
r=0.95 and r=0.91, all p<0.001) and acceptable agreement in Bland Altman 
analysis.21 Although it has been used extensively in pregnancy, the Arteriograph® 
has not been validated against invasive methods of arterial stiffness measurement 
during pregnancy, most likely for ethical and technical reasons. 
Statistical Analysis 
Data distribution was assessed using the Shapiro-Wilk test as well as graphical 
methods. Categorical data were presented as number and percentage, while 
continuous data were presented as the median and interquartile range (IQR). 
Statistical analysis was performed using the Chi-square test, Mann-Whitney test and 
T Test. The Bonferroni correction was applied to control for multiple comparisons. 
Linear regression was performed to determine which haemodynamic and maternal 
factors (heart rate, MAP, height, weight, age and gestational age) were associated 
with PWV and AIx. The differences in AIx and PWV according to ethnicity were 
tested using Mann-Whitney test or T Test. Multiple regression was performed to 
adjust for those factors that had a significant association. Linear regression was also 
used to adjust AIx to a heart rate of 75bpm as is commonly presented in the 
literature due to the known inverse relationship between heart rate and AIx.22 A p 
value <0.05 was considered statistically significant. Statistical software (SPSS 25.0; 
SPSS Inc., Chicago, IL) was used to conduct the analysis.  
 
 




Sixty-nine participants with HDP and SGA, 129 participants with HDP-only and 220 
normotensive controls were included in the analysis following the exclusion of 21 
women recruited as controls who subsequently gave birth to a SGA neonate. The full 
demographic and pregnancy characteristics are shown in Table 1. With the 
exception of maternal height and adjusted brachial AIx, the data was not normally 
distributed. There were significant differences in the maternal stature and ethnicity 
among the study groups. Women in the HDP with SGA group also gave birth to 
smaller babies at an earlier gestation than in both the other groups (Table 1).  
Maternal and pregnancy variables related to PWV and AIx 
Univariate linear regression analysis demonstrated that maternal age (p<0.001), 
weight (p=0.013), height (p=0.038) and heart rate (p<0.001) were significantly 
associated with brachial and aortic AIx, but gestational age (p=0.082) and MAP 
(p=0.407) were not.  For PWV, maternal weight (p<0.001), height (p=0.015), MAP 
(p=0.001), heart rate (p<0.001) and gestational age (p=0.025) were significant 
predictors, whilst maternal age (p=0.365), was not. Multiple regression models of 
these factors are shown in the supplementary material. There was no difference in 
PWV or AIx according to ethnicity (all >0.05), and it was therefore not included as a 
variable in the models. 
Comparison of PWV and AIx among the study groups 
Comparisons for crude and adjusted arterial stiffness results are displayed in Table 2 
and Figure 1. The HDP with SGA group had significantly (all p<0.001) higher 
unadjusted PWV (7.8m/s vs. 6.9m/s), unadjusted brachial AIx (-21.2% vs. -63.3%), 
unadjusted aortic AIx (26.9% vs. 5.6%), aortic augmentation index-75bpm (AIx-75) 
(25.9% vs. 0.69%) and sBPAo (137mmHg vs. 109 mmHg) compared to the control 
group. Heart rate was significantly lower (76 bpm vs. 86bpm, p<0.001). After 
adjustment for maternal factors, brachial and aortic AIx remained significantly higher 
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(both p<0.001) but there was no difference in PWV (7.1m/s vs 7.1m/s, p=0.836). The 
HDP-only group also had significantly (all p<0.001) higher unadjusted PWV (8.0m/s 
vs. 6.9m/s), unadjusted brachial AIx (-39.6% vs. -63.3%), unadjusted aortic AIx 
(17.4% vs. 5.6%), aortic AIx-75 (11.7% vs. 0.69%) and sBPAo (129mmHg vs. 109 
mmHg) compared to the control group. These results persisted after adjustment for 
maternal factors, with the exception of adjusted brachial AIx. There was no 
significant difference in heart rate between the HDP-only group and the control group 
(83bpm vs. 86bpm, p=0.073).  
 
When comparing the HDP with SGA group to the HDP-only group, the HDP with 
SGA group had significantly higher unadjusted brachial AIx (-21.2% vs. -39.6%, 
p<0.001), higher unadjusted aortic AIx (26.9% vs. 17.4%, p<0.001), higher aortic 
AIx-75 (25.9% vs. 11.7%), higher sBPAo (137mmHg vs. 129mmHg, p=0.003) and 
significantly lower heart rate (76bpm vs. 83bpm, p=0.002). There was no significant 
difference in unadjusted aortic PWV (p=0.414). After adjustment for maternal factors, 
brachial and aortic AIx remained significantly higher in the HDP with SGA group. 
Conversely, adjusted aortic PWV was significantly lower in HDP with SGA group 
(7.1m/s vs.7.7m/s, p<0.001). 
Supplementary analysis excluding patients taking antihypertensive medications at 
the time of assessment was performed. The differences between the hypertension 
with SGA group and the hypertension-only groups persisted with the exception of 
sBPAo and adjusted aortic AIx which were not significantly different (Supplementary 
table 1). 
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Discussion 
Summary of study findings 
Women with HDP have significantly higher aortic PWV and AIx compared to 
normotensive women. Furthermore, in pregnancies complicated by HDP with a SGA 
neonate, AIx is higher compared to pregnancies complicated by HDP without a SGA 
neonate. Maternal hemodynamic and anthropometric factors influence both AIx and 
PWV.  
Interpretation of study findings and comparison with the existing literature 
The finding of increased arterial stiffness in pregnancies complicated by HDP is in 
alignment with previous research.14,15,23–25 However, there is a paucity of data 
comparing pregnancies complicated by HDP with SGA neonate and those without. 
Previous studies have divided preeclampsia into early and late-onset disease and 
compared these two groups. Franz et al. described increased PWV and AIx using 
the Arteriograph® device in pregnancies complicated by preeclampsia and the 
measurements were higher in late-onset disease.14 Conversely, Yinon et al. only 
found a significant difference in AIx compared to controls in the early-onset group.26 
Others have compared women with gestational hypertension and preeclampsia. 
Spasojevic et al. reported increased AIx in both their gestational hypertension and 
preeclampsia groups compared to controls, but the difference was more marked in 
the preeclampsia group.25 The association of SGA neonate in preeclampsia is likely 
to be a consequence of placental hypoperfusion. This may be secondary to lower 
cardiac output and higher systemic vascular resistance observed in these 
pregnancies.27,28  
The finding of a higher AIx in pregnancies complicated by HDP with SGA compared 
to pregnancies with HDP-only, but no corresponding difference in PWV is likely to be 
due to the physiological mechanism behind each measurement. PWV is the speed at 
which the pulse travels along an arterial segment and is inversely related to arterial 
distensibility by the Bramwell-Hill formula. AIx is the measure of the magnitude of 
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increase in the systolic pressure profile in the artery by pressure waveform reflection. 
Distensibility is influenced by smooth muscle tone, endothelial activity and the 
collagen and elastin content of the artery.29–31 Whilst both PWV and AIx are 
influenced by arterial distensibility, AIx is more directly influenced by hemodynamic 
changes – specifically systemic vascular resistance.30,32,33 As the reflected waveform 
originates mainly in the distal resistance vessels, AIx is proportional to systemic 
vascular resistance. Higher systemic vascular resistance has been described in 
pregnancies complicated by preeclampsia with SGA neonate compared to both 
controls and HDP pregnancies without SGA neonate.34,35 Furthermore, PWV has a 
positive relationship with heart rate, which is significantly lower in pregnancies 
complicated by HDP with SGA. We have previously described lower heart rate as a 
contributory factor to lower cardiac output in preeclampsia. As such, it may be more 
appropriate to consider the unadjusted values for PWV, as a lower heart rate 
appears to be part of the preeclampsia disease process. Kaihura et al. reported 
increased PWV but not AIx in patients with preeclampsia following adjustment for 
confounding factors.24 They included all preeclampsia cases together, rather than 
defining by severity. Therefore, their findings may be in alignment with our finding of 
increased adjusted PWV in the HDP-only group. The lack of difference in AIx 
between their preeclampsia and control group may be because their regression 
calculation for AIx included an adjustment for MAP, a variable we did not find to 
make a significant contribution. 
 
Clinical and research implications 
There is increasing awareness regarding the link between preeclampsia and 
cardiovascular disease.2–4 The findings of this study support that association, 
particularly as arterial stiffness is a useful marker of vascular health in the general 
population.9,36,37 Small studies of postnatal arterial stiffness have demonstrated 
higher arterial stiffness following a pregnancy complicated by preeclampsia 
compared to a healthy pregnancy.26,38 It is unclear if these differences pre-date 
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pregnancy, or are a consequence of pregnancy itself. Mahendru et al. demonstrated 
higher postpartum AIx compared to preconception levels in healthy women39, but 
there are currently no preconception comparisons between women who 
subsequently develop preeclampsia and those that do not.  
Recently proposed first trimester screening models for preeclampsia include 
maternal factors, MAP, serum placental growth factor and uterine artery pulsatility 
index, with very good detection of early-onset preeclampsia (90% at a 10% screen 
positive rate), but modest detection for all preeclampsia (50% at a 10% screen 
positive rate).40 A previous study demonstrated that the combination of maternal 
factors, AIx, PWV and central systolic BP had a detection rate for all preeclampsia of 
56.9% at a false positive rate of 10%.12 Given that in this current study, MAP and AIx 
were independent of each other, the addition of AIx to the screening models may 
improve performance, particularly with regard to term preeclampsia.  
Study limitations and strengths 
The main strengths of this study are that it includes a large cohort of clearly defined 
hypertensive women and a large control group for comparison. The participants were 
recruited prospectively, and their pregnancy outcomes were carefully ascertained. 
Moreover, we have adjusted for the effect of confounding maternal factors and 
gestational age. One limitation is that we included patients who had been taking 
antihypertensive medication at the time of assessment. This could have an effect on 
arterial stiffness. However, the results were unchanged when repeating the analysis 
excluding these patients. Secondly, some women included in the control group were 
recruited when attended an ultrasound for suspicion of a small or large for dates 
fetus. Although we only included those with a normal scan and a normal birthweight 
at delivery, our control population was not fully unselected, and an element of bias 
could have been introduced. Finally, although the Arteriograph® device is simple and 
non-invasive to use, the results that it gives cannot be used interchangeably with 
those of other devices.  
Conclusion 
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Pregnancies complicated by HDP have significantly higher PWV and AIx compared 
to normotensive control pregnancies. The AIx was higher in those pregnancies 
complicated by HDP with SGA neonate compared to HDP pregnancies with an 
appropriately grown neonate,  
reflecting a progression in severity of arterial stiffness abnormality with a worsening 
clinical picture. These findings most likely reflect systemic reduced vascular 
compliance and increased systemic vascular resistance in HDP pregnancies. 
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Figure 1. Box diagrams demonstrating (top to bottom) adjusted Augmentation Index, 
Heart Rate and Unadjusted Pulse Wave Velocity in the HDP with SGA, the HDP-only 
and the Control groups. *Indicates P<0.05 compared to the control group. ** 
indicates P<0.05 compared to the HDP-only group. 
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Table 1. Maternal and pregnancy characteristics of women in the hypertension with small for gestational age group, the 
hypertension-only group and the control group. 
 
 Group P value 
 Hypertension 



























33.4 (30.0 to 
35.3) 
36.4 (34.4 to 38.1) 36.0 (31.5 to 
36.6) 
<0.001 <0.001 <0.001 
Maternal height 
(cm) 
161 (157 to 
165) 
166 (160 to 171) 165 (159 to 
170) 




78.5 (68.2 to 
92.7) 
86.0 (76.3 to 98.5) 75.6 (67.9 to 
83.9) 








109 (103 to 
114) 
107 (100 to 112 ) 88 (83 to 94 ) <0.001 <0.001 0.183 





76 (71 to 85) 83 (75 to 92) 86 (77 to 94) <0.001 0.073 0.002 
Gestation at 
delivery (weeks) 
35.7 (31.9 to 
37.9) 
39.0 (37.6 to 40.0 40.0 (38.9 to 
40.9) 
<0.001 <0.001 <0.001 
Birthweight 
centile 
2.6 (0.77 to 
5.5) 
43.5 (22.5 to 74.8) 40.7 (24.8 to 
67.9) 







































22 (31.9) 24 (18.6) 0 (0) - - 0.035 
 
 
The values represent median (IQR) or number (%). Post-hoc Bonferroni correction; significance at P<0.004 
This article is protected by copyright. All rights reserved.
 
Table 2. Unadjusted and adjusted arterial stiffness values of women in the hypertension with small for gestational age group, the 
hypertension-only group and the control group. 
 
 Group P value 
 Hypertension 
with small for 












only vs Control 
Hypertension 








137 (124 to 154) 129 (119 to 
137) 
106 (98 to 
114) 
<0.001 <0.001 0.003 
Brachial 
augmentation 
index (%)  
-21.2 (-39.5 to -
1.2) 








26.9 (17.5 to 
36.6) 
17.4 (9.7 to 
26.2) 
5.6 (0.85 to 
11.5) 




25.9 (13.7 to 
38.9) 
11.7 (2.0 to 
24.8) 
0.62 (-7.1 to 
8.0) 
<0.001 <0.001 <0.001 
Pulse wave 
velocity (m/s) 
7.8 (7.1 to 8.9) 8.0 (7.2 to 9.3) 6.9 (6.1 to 
7.9) 




-52.0 (-60.0 to -
47.6) 




<0.001 0.035 <0.001 
Adjusted Aortic 12.5 (7.4 to 15.7) 10.0 (5.1 to 7.6 (3.6 to <0.001 0.003 0.002 






wave velocity (m/s) 
† 
7.1 (6.7 to 7.5) 7.7 (7.1 to 8.3)  7.1(6.6 to 
7.6) 
0.836 <0.001 <0.001 
* Central Systolic blood pressure as measured by the Arteriograph® device. Aortic augmentation index-75bpm= Aortic 
augmentation index adjusted to a heart rate of 75 bpm. † Adjusted Brachial Augmentation Index= 107.887 + (age x 0.519) + 
(weight x 0.135) – (height x 0.902) – (heart rate x 0.543), R2= 0.193, p<0.001. Adjusted Aortic Augmentation Index = 96.495 + (age 
x 0.538) + (weight x 0.149) – (height x 0.549) – (heart rate x 0.316), R2=0.154, p<0.001. Adjusted Pulse Wave Velocity = -4.694 + 
(weight x 0.027) + (height x 0.028) + (mean arterial pressure x 0.014) + (heart rate x 0.029) + (gestational age x 0.041), R2= 0.244, 
p<0.001. Post-hoc Bonferroni correction; significance at P<0.006 
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